AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Company Description
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide.
It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas.
The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization.
It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA.
Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies.
It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels.
It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer.
It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc.
Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
Country | United States |
IPO Date | Jun 17, 1983 |
Industry | Drug Manufacturers - General |
Sector | Healthcare |
Employees | 26,700 |
CEO | Robert A. Bradway |
Contact Details
Address: One Amgen Center Drive Thousand Oaks, California United States | |
Website | https://www.amgen.com |
Stock Details
Ticker Symbol | AMGN |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0000318154 |
CUSIP Number | 031162100 |
ISIN Number | US0311621009 |
Employer ID | 95-3540776 |
SIC Code | 2836 |
Key Executives
Name | Position |
---|---|
Robert A. Bradway | Chairman, Chief Executive Officer & President |
Dr. David M. Reese M.D. | Executive Vice President & Chief Technology Officer |
Peter H. Griffith | Executive Vice President & Chief Financial Officer |
Scott Skellenger | Senior Vice President & Chief Information Officer |
Dr. Howard Y. Chang M.D., Ph.D. | Senior Vice President of Global Research & Chief Scientific Officer |
Esteban Santos | Executive Vice President of Operations |
Jonathan P. Graham J.D. | Executive Vice President, General Counsel & Secretary |
Justin G. Claeys | Vice President of Investor Relations |
Matthew C. Busch | Chief Accounting Officer & Vice President of Finance |
Murdo Gordon | Executive Vice President of Global Commercial Operations |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Dec 06, 2024 | 4 | Filing |
Dec 03, 2024 | 4 | Filing |
Nov 06, 2024 | 4 | Filing |
Nov 06, 2024 | 4 | Filing |
Nov 06, 2024 | 4 | Filing |
Nov 06, 2024 | 4 | Filing |
Nov 06, 2024 | 4 | Filing |
Oct 31, 2024 | 10-Q | Quarterly Report |
Oct 30, 2024 | 8-K | Current Report |
Aug 23, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |